News

Caretaker Medical Receives Inaugural Healthcare Tech Innovation Award and $200,000 Grant from Medical Society of D.C.

Caretaker Medical is honored to announce it has been awarded the Healthcare Technology Innovation Award, along with a $200,000 grant, from the Medical Society of the District of Columbia (MSDC) at the 5th annual Capital Healthcare Honors Gala. This prestigious award, presented on March 26, 2025, recognizes Caretaker Medical’s groundbreaking work in advancing wireless patient monitoring with its VitalStream platform.

The award, supported by a grant from The Institute for Technology in Healthcare, commemorates the legacy of Dr. Cesar A. C. Caceres, an esteemed medical professional dedicated to the application of technology to solve healthcare challenges. Dr. Caceres founded the Institute for Technology in Healthcare and was recognized for his pioneering work in computer-electrocardiographic interpretive systems.

“We are delighted to celebrate the memory and achievements of Dr. Caceres by presenting Caretaker Medical with this inaugural award,” said Matthew Lecuyer, MD, Healthy Physician Foundation board chair. “As technology improves patient care and physician wellbeing, this award connects the achievements of the past with the promise of the future.”

Caretaker Medical’s CEO, Jeff Pompeo, accepted the award on behalf of the company, expressing gratitude for the recognition of their commitment to improving patient care and physician health. “This award validates our dedication to providing patients and physicians with a much-needed wearable, continuous blood pressure monitoring solution,” said Pompeo.

VitalStream, Caretaker Medical’s US Food and Drug Administration-cleared wearable monitor, merges clinical accuracy with a wire-free, comfortable patient experience. The $200,000 grant will support the expansion of this innovative platform, which provides continuous blood pressure and hemodynamic monitoring.

The technology has demonstrated versatility in routine care and crisis response, proving invaluable in applications such as maternal health monitoring, perioperative recovery, and during the recent IV fluid shortages caused by Hurricane Helene. In these challenging times, VitalStream has helped healthcare providers maintain continuous blood pressure monitoring, ensuring patient safety and optimizing fluid management.

“VitalStream offers significant advantages for patients and providers in routine conditions, as well as unexpected and demanding circumstances,” said Johnny Mann, vice president of sales and marketing at Caretaker Medical. “Our technology can help ensure patient safety and optimize fluid management during some of the most challenging times.”

Caretaker Medical extends its deepest gratitude to the MSDC and The Institute for Technology in Healthcare for this honor and for their tireless efforts to advance healthcare in the Nation’s Capital Region and beyond.

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and